<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
----------------
FORM 10-Q
[X] Quarterly report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934.
For the Quarter Ended March 31, 1997
[ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934.
For the transition period from to
---------- ------
Commission file number 0-19880
ENDOSONICS CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 68-0028500
(State or other jurisdiction of (I.R.S. Employer
incorporated or organization) Identification No.)
2870 Kilgore Road, Rancho Cordova, California 95670
(Address of principal executive offices)
Registrant's telephone number, including area code (510) 734-0464
Indicate by check mark whether the Registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes X No
--- ---
On March 31, 1997, the registrant had outstanding 13,550,666 shares of Common
Stock of $.001 par value, which is the registrant's only class of Common Stock.
This report on Form 10-Q including all exhibits, contains 16 pages.
<PAGE> 2
ENDOSONICS CORPORATION
FORM 10-Q
FIRST QUARTER
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page
<S> <C> <C>
Part I. Financial Information
Item 1. Consolidated Financial Statements
Consolidated balance sheets at March 31, 1997 and
December 31, 1996..................................................................... 3
Consolidated statements of operations for the three months
ended March 31, 1997 and 1996..................................................... 4
Condensed consolidated statements of cash flows for the
three months ended March 31, 1997 and 1996........................................ 5
Notes to condensed consolidated financial statements..................................... 6
Item 2. Management's discussion and analysis of financial condition
and results of operation................................................................. 9
Part II. Other Information........................................................................ 11
Item 1 through 5. Not Applicable.
Item 6.............................................................................................. 13
(a) Exhibits:
Exhibit 27 -- Financial Data Schedule
(b) Reports on Form 8-K.
Signatures.......................................................................................... 14
Exhibit Index....................................................................................... 16
</TABLE>
2
<PAGE> 3
ENDOSONICS CORPORATION
CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except share and per share amounts)
<TABLE>
<CAPTION>
March 31, December 31,
1997 1996
---------- ------------
<S> <C> <C>
ASSETS
Current assets:
Cash and equivalents $36,350 $ 34,943
Short-term investments -- 5,249
Trade accounts receivable, net 7,917 5,682
Inventories 3,382 3,572
Accrued interest receivable and other current assets 925 1,202
------- --------
Total current assets 48,574 50,648
Property and equipment, net 2,155 1,947
Investment in Cardiometrics, Inc. 2,317 --
Investment in CardioVascular Dynamics, Inc. 19,290 19,444
Other non-current assets 29 --
------- --------
$72,365 $ 72,039
======= ========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses $ 5,474 $ 5,969
Deferred distributorship fee revenue -- 3
SHAREHOLDERS' EQUITY
Convertible preferred stock, $.001 par value
5,000,000 shares authorized, no shares issued and outstanding - -
Common stock, $.001 par value; 25,000,000 shares
authorized as of December 31, 1996; and 13,550,666
and 13,522,572 shares issued and outstanding as of
March 31, 1997 and December 31, 1996, respectively 14 14
Additional paid-in capital 124,424 124,024
Accumulated deficit (57,495) (58,000)
Unrealized (gain) loss on available-for-sale securities (3) 1
Foreign currency translation (49) 28
Total shareholder's equity 66,891 66,067
-------- --------
$ 72,365 $ 72,039
======== ========
</TABLE>
See accompanying notes
3
<PAGE> 4
ENDOSONICS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands except share and per share amounts)
<TABLE>
<CAPTION>
Three Months Ended March 31,
----------------------------
1997 1996
-------- -------
<S> <C> <C>
Revenues:
Product sales $ 6,221 $ 5,182
License fee -- 100
Contract revenue 109 390
-------- --------
Total revenue 6,330 5,672
Cost of sales 3,419 3,496
-------- --------
Gross margin 2,911 2,176
Operating expenses:
Research, development and clinical 1,016 1,613
Marketing and sales 906 1,555
General and administrative 829 856
-------- --------
Total operating expenses 2,751 4,024
Income (loss) from operations 160 (1,848)
Equity in net loss of CVD (269) --
Other income:
Interest income 611 591
Distributorship fees 3 18
-------- --------
Total other income 614 609
-------- --------
Net income (loss) $ 505 ($ 1,239)
======== ========
Net (loss) per share ($0.09)
========
Earnings Per Share
Primary $0.03
========
Fully Diluted $0.03
========
Basic $0.04
========
Diluted $0.03
========
Shares used in the calculation of net (loss) per share 13,094,157
==========
Shares used in the calculation of net income per share Primary 15,270,617
==========
Fully Diluted 15,270,617
==========
Basic 13,547,464
==========
Diluted 15,270,617
==========
</TABLE>
See accompanying notes
4
<PAGE> 5
ENDOSONICS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
<TABLE>
<CAPTION>
Three months ended March 31,
1997 1996
------------- -----------
<S> <C> <C>
Cash flows from operating activities
Net income (loss) $ 505 ($1,239)
Adjustments to reconcile net income (loss) to net
cash used in operating activities:
Amortization of deferred compensation -- 26
Depreciation and amortization 149 175
Equity in net loss of CVD 269 --
Net changes in:
Operating assets (1,874) (42)
Operating liabilities and deferred revenue (498) (6)
-------- --------
Net cash used in operating activities (1,449) (1,086)
Cash flows from investing activities:
Purchase of short-term investments -- (11,859)
Sales of short-term investments 56 80
Maturities of short-term investments 5,189 6,108
Purchase of Cardiometrics Common Stock (2,317) --
Capital expenditures for property and equipment (357) (207)
-------- --------
Net cash provided by investing activities 2,571 (5,878)
Cash flows from financing activities:
Proceeds from common stock issuance to Cordis
Corporation -- 5,000
Proceeds from exercise of options 285
1,718
-------- --------
Net cash provided by financing activities 285
6,718
Net (decrease) increase in cash and equivalents 1,407 (246)
Cash and equivalents, beginning of period 34,943 36,757
======== ========
Cash and equivalents, end of period $ 36,350 $ 36,511
======== =======
</TABLE>
See accompanying notes.
5
<PAGE> 6
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 1997
(UNAUDITED)
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The interim financial information is unaudited. In the opinion of management of
EndoSonics Corporation ("EndoSonics" or the "Company"), the condensed
consolidated financial statements included in this report reflect all
adjustments necessary, consisting only of normal recurring adjustments, to
present fairly the Company's consolidated financial position at March 31, 1997
and the consolidated results of its operations and cash flows for the three
month period ended March 31, 1997, and 1996. Results for the interim periods are
not necessarily indicative of consolidated results to be expected for the entire
fiscal year. These financial statements should be read in conjunction with the
Company's audited financial statements for the year ended December 31, 1996,
contained in the Company's Annual Report on Form 10-K.
PRINCIPLES OF CONSOLIDATION
The consolidated financial statements include the accounts of EndoSonics
Corporation (the "Company"), a Delaware Corporation, and its wholly-owned
subsidiaries. All significant intercompany accounts and transactions have been
eliminated. Investments in unconsolidated subsidiaries, and other investments in
which the Company has a 20% to 50% interest or otherwise has the ability to
exercise significant influence, are accounted for under the equity method (see
Note 4).
INVESTMENTS
In accordance with SFAS 115, the Company has divided its investment portfolio
into held-to-maturity and available-for-sale categories. Unrealized losses on
available-for-sale securities are recorded as a separate component of
shareholders' equity.
2. INVENTORIES
Inventories are stated at the lower of cost, determined on an average cost
basis, or market value. Inventories consist of the following:
<TABLE>
<CAPTION>
March 31, 1997 December 31, 1996
-------------- -----------------
<S> <C> <C>
Raw materials $ 963 $ 798
Work-in-process 1,635 1,181
Finished goods 784 1,593
------- -------
Total $ 3,382 $ 3,572
======= =======
</TABLE>
3. COMPUTATION OF NET INCOME (LOSS) PER SHARE
Net (loss) per share is computed using the weighted average number of shares of
common stock outstanding. Common equivalent shares from stock options are
excluded from the computation of net (loss) per share because their effect is
antidilutive. Conversely, common equivalant shares from stock options are
included in the computation of net income per share as their effect is dilutive.
6
<PAGE> 7
In February 1997, the Financial Accounting Standards Board issued Statement No.
128, Earnings per Share, which is required to be adopted on December 31, 1997.
At that time, the Company will be required to change the method currently used
to compute earnings per share and to restate all prior periods. Under the new
requirements for calculating primary earnings per share, the dilutive effect of
stock options will be excluded. The impact is expected to be immaterial. The
impact of Statement 128 on the calculation of fully diluted earnings per share
for the quarter ended March 31, 1997 and March 31, 1996 is not expected to be
material.
4. CHANGE IN OWNERSHIP PERCENTAGE OF CARDIOVASCULAR DYNAMICS, INC.
On June 19, 1996, EndoSonics' 84% owned subsidiary, CardioVascular Dynamics,
Inc. (CVD), successfully completed an Initial Public Offering (IPO) of 3,400,000
shares of common stock at $12.00 per share, followed by an additional 510,000
shares issued in July 1996 (over-allotment option granted to CVD's
underwriters). As of March 31, 1997, EndoSonics owned 45% of the outstanding
shares of CVD. As a result of this transaction, CVD's results of operations are
accounted for on the equity method. In the quarter ended March 31, 1997, the
Company recorded $269 representing its proportionate share of CVD's net losses
for the period. Financial information for CVD is shown below:
BALANCE SHEET INFORMATION - CVD
<TABLE>
<CAPTION>
(Unaudited) March 31, 1997
--------------
(In thousands)
<S> <C>
Current assets $48,049
Property and equipment, net 1,311
Other assets 431
-------
Total assets $49,791
=======
Current liabilities $ 2,494
Deferred distributorship fee revenue 17
Stockholders' equity 47,280
-------
Total liabilities and stockholders' equity
$49,791
=======
EndoSonics' share of CVD's net assets $19,290
=======
STATEMENT OF OPERATIONS - CVD
(Unaudited) Three Months Ended
(In thousands) March 31, 1997
--------------
Total revenue $ 3,019
Cost of sales 1,416
-------
Gross profit 1,603
Total operating expenses 2,786
-------
Loss from operations (1,183)
--------
Other income (expense) 585
========
Net loss ($598)
========
EndoSonics' share of net losses of CVD ($269)
========
</TABLE>
7
<PAGE> 8
Cardio Vascular Dynamics, Inc., stock is quoted on The Nasdaq Stock Market. The
closing price of CVD's stock at March 31, 1997 was $10.00 per share. The Company
held 4,040,000 shares of CVD's common stock at March 31, 1997.
5. RESTRUCTURING AND OTHER CHARGES
In June 1996, the Company recorded restructuring and other charges of
approximately $3.1 million in connection with the consolidation of the Company's
IVUS manufacturing operations and with the start-up production of the new
Five-64 imaging devices. The elements of the total charges as of March 31,
1997 are as follows:
<TABLE>
<CAPTION>
(In Thousands)
Representing
Asset Future
Provision Write-Downs Cash Outlays
--------- -------------- ------------
<S> <C> <C> <C>
Consolidation of facilities $ 994 $ 994
Conversion to new technology 1,849 $ 808 1,041
Corporate reorganization 223 223
-------- ------ ------
$ 3,066 $ 808 $2,258
======== ====== ======
</TABLE>
As of March 31, 1997, the reserve for restructuring and other charges was
approximately $906.
6. PENDING BUSINESS ACQUISITION
On January 27, 1997, EndoSonics Corporation and Cardiometrics, Inc., jointly
announced the signing of a definitive merger agreement for a transaction value
at approximately $9.00 per share of Cardiometrics common stock or $66.7 million.
Under the merger agreement approved by the boards of both companies,
Cardiometrics' stockholders will receive 0.35 newly issued shares of EndoSonics
common stock, 0.20 shares of CardioVascular Dynamics, Inc., common stock, held
by EndoSonics, and $2.00 cash, in exchange for each share of Cardiometrics
common stock. The CVD exchange ratio will be increased up to a maximum of 0.2636
per Cardiometrics common share if the total merger consideration is less than
$9.00 per Cardiometrics common share during a specified period immediately
preceding the stockholders meeting of Cardiometrics to approve the merger.
EndoSonics has the right to substitute cash for these additional CVD shares. CVD
is a 45%-owned publicly-traded subsidiary of EndoSonics.
The merger is subject to the approval of the stockholders of Cardiometrics and
certain regulatory approvals. It is anticipated that the combination will be
accounted for under the purchase method of accounting. Cardiometrics also
granted EndoSonics an option to purchase up to 19.9% of its outstanding shares
exercisable only on the occurrence of specified events including termination of
the merger agreement following commencement of a tender offer by a third party
for Cardiometrics. As of March 31, 1997, EndoSonics held 300,000 shares of
Cardiometrics common stock.
8
<PAGE> 9
Also, in January 1997, the Board of Directors of EndoSonics approved a dividend
of .04 shares of CVD common stock to be paid on each outstanding share of
EndoSonics common stock with the record date and exact date of distribution to
be determined after the close of merger described above.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
This Quarterly Report on Form 10-Q contains forward looking statements. The
Company's business is subject to risks and uncertainties and the Company's
actual results may differ significantly from the results discussed in the
forward looking statements. Factors that might cause such a difference include,
but are not limited to, the Company's relationship with Cordis Corporation and
the effect on Cordis of its acquisition by Johnson & Johnson, Inc., scale-up of
the Company's manufacturing operations for the Company's existing products and
the introduction of new products, FDA approval of new products and changes in
regulatory requirements and third-party reimbursement policies. For a discussion
of these and other factors, please see "Risk Factors" in the Company's Annual
Report on Form 10-K for the fiscal year ended December 31, 1996.
OVERVIEW
Since its inception in 1984, EndoSonics has been engaged primarily in the
research and development of products for the diagnosis and treatment of
cardiovascular disease. Since 1991, a majority of the Company's net revenue has
been derived from sales of its IVUS imaging systems and catheters.
The Company markets and distributes its IVUS imaging products in the United
States, Europe and Japan through relationships with strategic partners, certain
other distributors and, to a lesser extent, through a direct sales force. In
February 1996, EndoSonics and Cordis Corporation (a Johnson & Johnson Company)
entered into an Exclusive Distribution Agreement pursuant to which Cordis was
granted the exclusive right to distribute EndoSonics' IVUS imaging products for
coronary applications in North America, Europe, Africa and the Middle East. The
Exclusive Distribution Agreement supersedes and replaces a prior distribution
agreement between Cordis and EndoSonics and a prior distribution agreement
between EndoSonics Netherlands B.V., a wholly owned subsidiary of EndoSonics,
and Cordis S.A. Cordis is obligated during each year of the Exclusive
Distribution Agreement to use reasonable efforts to purchase certain minimum
annual amounts of products from EndoSonics. Subject to certain exceptions,
Cordis' failure to meet the minimum annual purchase amount during any year of
the Exclusive Distribution Agreement shall constitute a material breach of such
agreement. Cordis is also obligated during the term of the Exclusive
Distribution Agreement to undertake certain efforts to market, promote,
distribute and sell EndoSonics' IVUS imaging products, including the provision
of adequate personnel and facilities, the maintenance of sufficient inventory
for demonstration purposes and the appointment of a United States and European
intracoronary ultrasound marketing manager to interface with EndoSonics' United
States and European clinical and support staff. The Exclusive Distribution
Agreement also contains standard representations and warranties of each party
and standard provisions regarding indemnification, service and maintenance and
confidentiality. Under the terms of the Exclusive Distribution Agreement, Cordis
shall purchase IVUS imaging products from EndoSonics at agreed upon prices set
forth in such agreement, which prices shall be jointly reviewed by EndoSonics
and Cordis every six months. The Exclusive Distribution Agreement initially
expires on December 31, 1998, but may be extended by the parties for successive
one year periods. In connection with the execution of the Exclusive Distribution
Agreement, the
9
<PAGE> 10
Company issued 350,877 shares of Common Stock to Cordis in a private placement
transaction for an aggregate purchase price of approximately $5,000,000. The
Company has since registered the shares of Common Stock issued to Cordis. The
Company and Cordis are currently in discussions with regard to amending the
Exclusive Distribution Agreement to cover both South America and Japan.
CardioVascular Dynamics, Inc., formerly an 84%-owned subsidiary of the Company's
designs, develops, manufactures and markets catheters used to treat certain
vascular diseases. CVD's catheters are used in conjunction with angioplasty and
other interventional procedures such as vascular stenting and drug delivery.
CVD's proprietary FOCAL and Multiple Microporous Membrane ("M3") technologies
enable physicians to deliver therapeutic radial force, stents, drugs or contrast
media accurately and effectively to the treatment site in addition to allowing
the perfusion of blood during an interventional procedure. CVD's catheters are
designed to address three principal challenges facing cardiologists: restenosis
of a treated vessel, chronic total occlusions and acute reclosure of a vessel
during or soon after a procedure. CVD completed its initial public offering in
June of 1996 and, as a result, its assets, liabilities and results of operations
are no longer included in the Company's consolidated financial statements. The
Company currently holds approximately 45% of the outstanding shares of the
Common Stock of CVD and accounts for its investment on the equity method.
The Company's business strategy includes acquiring related businesses, products
or technologies. In January 1997, the Company entered into an agreement to
acquire Cardiometrics, Inc. through the merger of a wholly-owned subsidiary of
the Company with and into Cardiometrics, with Cardiometrics surviving as a
wholly-owned subsidiary of the Company. The Company expects to incur an
approximate $40 million dollar in-process research and development charge as a
result of the acquisition. The Company expects that it may pursue additional
acquisitions in the future. Any future acquisitions may result in potentially
dilutive issuances of equity securities, the write-off of in process research
and development, the incurrence of debt and contingent liabilities and
amortization expenses related to intangible assets acquired, any of which could
materially adversely affect the Company's business financial condition and
results of operations. In particular, if the Company is unable to use the
"pooling of interests" method of accounting, the Company will be required to
amortize any intangible assets acquired in connection with any additional
acquisitions and the amortization periods for such costs will be over the useful
lives of such assets, which range from three years to eight years. Additionally,
unanticipated expenses may be incurred relating to the integration of
technologies and research and development and administrative functions. Any
acquisition will involve numerous risks, including difficulties in the
assimilation of the acquired Company's employees, operations and products,
uncertainties associated with operating in new markets and working with new
customers, the potential loss of the acquired Company's key employees as well as
the costs associated with completing the acquisition and integrating the
acquired Company.
The Company acquired Du-Med BV ("Du-Med") in 1994 in order to obtain micromotor
IVUS technology and subsequently established the Company's European headquarters
at DuMed's facility in The Netherlands.
In 1993, the Company introduced both its Oracle Imaging System, a platform
upgrade from its previous system, and enhanced imaging catheters. The Company
also commenced the Pinnacle Development Project, which involved the development
of new IVUS technology and resulted in the Five-64 catheter line and an enhanced
Oracle Imaging System. The Company announced the receipt of FDA approval to
market these products in October 1995. In addition, the Company announced the
receipt of a PMA to market its FOCAL catheter in October 1995. CVD began sales
of the FOCAL catheter in 1995. The Company began commercial sales of the
enhanced Oracle Imaging System in the fourth quarter of 1995 and began
commercial sales of the Five-64 catheter line in the first quarter of 1996. The
Company is currently expanding its manufacturing capacity for these new
products. The Company's financial results will be affected in the future by
certain factors, including
10
<PAGE> 11
the scaling up of manufacturing for the Company's Five-64 catheter line, market
acceptance of the Company's new products and the revenue mix between sales of
imaging systems and catheters and changes in government regulation regarding
third-party reimbursement applicable to the Company's System and Products.
RESULTS OF OPERATIONS
FIRST QUARTER OF 1997 COMPARED TO THE SAME PERIOD IN 1996
Total Revenue. Total revenue increased 12% to $6.3 million for the first quarter
of 1997, which included no CVD revenue, from $5.7 million for the first quarter
of 1996, which included $2.0 million of CVD revenue. Revenues for the IVUS
business increased 74% from $3.6 million in the first quarter of 1996. The
principal reasons for this increase are continued growth in demand for IVUS
products both in the U.S. and overseas markets, and increased sales through the
Company's agreement with Cordis Corporation. Further growth is dependent on the
ability of the Company to increase production of its new Five/64 catheters to
levels anticipated to meet demand for the product in both the U.S. and overseas
markets.
Cost of Sales. Cost of sales as a percentage of product sales decreased to 54%
for the first quarter of 1997 (all IVUS) from 62% in the first quarter of 1996,
which included $0.9 million of CVD cost of sales. For the IVUS business, cost of
sales decreased from 70% in the first quarter of 1996. Cost of sales as a
percentage of product sales in 1997 was reduced principally by volume increases
and improved manufacturing efficiencies. Gross profit margins for the IVUS
business were 46% for the first quarter of 1997 as compared to 30% for the first
quarter of 1996. Due to the uncertainty associated with continued improvements
in the efficiency of the Company's manufacturing process and the impact of
increasingly competitive pricing, there can be no assurance that the Company's
gross profit margin will be maintained or continue to improve in future periods.
Other Research, Development and Clinical. Other research, development and
clinical decreased to $1.0 million (all IVUS) for the first quarter of 1997 as
compared to $1.6 million for the first quarter of 1996, which included $0.6
million of CVD other research, development and clinical.
Marketing and Sales. Marketing and sales expenses decreased to $0.9 million for
the first quarter of 1997 (all IVUS) from $1.6 million for the first quarter of
1996, which included $0.6 million of CVD marketing and sales expenses. The
decrease of 8% from $1.0 million in the first quarter of 1996 for the IVUS
business is primarily the result of a stabilization of costs associated with
increased staffing and marketing programs both International and in the United
States in support of higher sales. As a percentage of total revenue, marketing
and sales expenses for IVUS decreased to 14% for the three months ended March
31, 1997 compared to 27% for the three months ended March 31, 1996, due
primarily to increased revenues.
General and Administrative. General and administrative expenses decreased
slightly to $0.8 million for the first quarter of 1997 (all IVUS) from $0.9
million (including CVD) for the first quarter of 1996. For the IVUS business,
general and administrative expenses increased 47% from $0.6 million in the first
quarter of 1996 due to an overall increase in the Company's level of operations.
As a percentage of total IVUS revenues, general and administrative expenses
decreased to 13% for the three months ended March 31, 1997, as compared to 15%
of total revenue for the three months ended March 31, 1996 due to increased
revenue.
Other Income, Net. Other income remained at $0.6 million for both the three
months ended March 31, 1997 and March 31, 1996.
11
<PAGE> 12
Net Income. Net income increased to $0.5 million, or $0.03 per share for
Primary, Fully Diluted, and Diluted EPS and $0.04 for Basic EPS for the three
months ended March 31, 1997, as compared to a net loss of $1.2 million, or
($0.09) per share, for the three months ended March 31, 1996. First quarter 1997
included $0.3 million of losses of CVD which the Company accounts for using the
equity method. On a comparable basis, the IVUS business reported a net income of
$0.8 million for the first quarter of 1997 as compared to a net loss of $0.9
million for the first quarter of 1996.
Liquidity and Capital Resources At March 31, 1997, the Company had cash, cash
equivalents and short-term investments of $36.4 million and no borrowings or
credit facilities. Net cash used in operations was $1.4 million in 1997, as
compared to $1.0 million in 1996. Cash used in operating activities includes
primarily increases in accounts receivable versus 1996 levels, and increases in
current liabilities. The Company anticipates using cash resources primarily for
capital expenditures, product development, sales and marketing, and working
capital purposes, prior to achieving positive cash flow from operations. The
Company believes that its existing cash, cash equivalents, and short-term
investments as of March 31, 1997 will be sufficient to meet the Company's
operating expenses and capital requirements through 1997. However, there can be
no assurance that the Company will not be required to seek other financing or
that such financing, if required, will be available on terms satisfactory to the
Company.
12
<PAGE> 13
OTHER INFORMATION
Items 1 through 5. Not applicable.
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits:
Exhibit 27 Financial Data Schedule
(b) On February 10, 1997, the Company filed a report on Form 8-K, for an
item 5 event regarding its proposed acquisition of Cardiometrics, Inc. and
the related Agreement and Plan of Reorganization.
13
<PAGE> 14
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ENDOSONICS CORPORATION
/s/ Reinhard Warnking
---------------------
Reinhard Warnking
President and
Chief Executive Officer
Date: May 11, 1997
/s/ Donald D. Huffman
---------------------
Donald D. Huffman
Vice President-Finance,
Chief Financial Officer, and
Principal Accounting Officer
Date: May 11, 1997
14
<PAGE> 15
EXHIBIT INDEX
27 Financial Data Schedule
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1997
<PERIOD-END> MAR-31-1997
<CASH> 36,350
<SECURITIES> 0
<RECEIVABLES> 7,917
<ALLOWANCES> 0
<INVENTORY> 3,382
<CURRENT-ASSETS> 48,574
<PP&E> 2,155
<DEPRECIATION> 0
<TOTAL-ASSETS> 72,365
<CURRENT-LIABILITIES> 5,474
<BONDS> 0
0
0
<COMMON> 14
<OTHER-SE> 66,877
<TOTAL-LIABILITY-AND-EQUITY> 72,365
<SALES> 6,221
<TOTAL-REVENUES> 109
<CGS> 3,419
<TOTAL-COSTS> 2,751
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> 505
<INCOME-TAX> 0
<INCOME-CONTINUING> 505
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 505
<EPS-PRIMARY> .03
<EPS-DILUTED> .03
</TABLE>
